TP53 and cancer: The N6-Methyladenosine (m6A) modification plays critical roles in cancer progression [66], while histone lactylation enhances m6A site binding, leading to period1 Circadian Regulator 1 (PER1) and Cellular tumor antigen p53 (TP53) degradation ocular melanoma [10].